Azole Drugs Trap Cytochrome P450 EryK in Alternative Conformational States

被引:17
|
作者
Montemiglio, Linda Celeste
Gianni, Stefano
Vallone, Beatrice
Savino, Carmelinda [1 ]
机构
[1] Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy
关键词
STRUCTURAL BASIS; C-12; HYDROXYLASE; ACTIVE-SITE; P450; INHIBITION; CHEMISTRY; MECHANISM; BACTERIAL; BINDING; CYP51;
D O I
10.1021/bi101062v
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
EryK is a bacterial cytochrome P450 that catalyzes the last hydroxylation occurring during the biosynthetic pathway of erythromycin A in Streptomyces erythraeus. We report the crystal structures of EryK in complex with two widely used azole inhibitors: ketoconazole and clotrimazole. Both of these ligands use their imidazole moiety to coordinate the heme iron of P450s. Nevertheless, because of the different chemical and structural properties of their N1-substituent group, ketoconazole and clotrimazole trap EryK, respectively, in a closed and in an open conformation that resemble the two structures previously described for the ligand-free EryK. Indeed, ligands induce a distortion of the internal helix I that affects the accessibility of the binding pocket by regulating the kink of the external helix G via a network of interactions that involves helix F. The data presented thus constitute an example of how a cytochrome P450 may be selectively trapped in different conformational states by inhibitors.
引用
收藏
页码:9199 / 9206
页数:8
相关论文
共 50 条
  • [21] Cytochrome P450
    Poulos, TL
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 1995, 5 (06) : 767 - 774
  • [22] Hepatic cytochrome P450 regulation in disease states
    Cheng, PY
    Morgan, ET
    CURRENT DRUG METABOLISM, 2001, 2 (02) : 165 - 183
  • [23] Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase
    Guengerich, F. Peter
    Martin, Martha V.
    Sohl, Christal D.
    Cheng, Qian
    NATURE PROTOCOLS, 2009, 4 (09) : 1245 - 1251
  • [24] Cytochrome p450 recognition sites for NADPH cytochrome p450 reductase
    Dai, R
    Robinson, RC
    Friedman, FK
    BIOPHYSICAL JOURNAL, 1996, 70 (02) : SU162 - SU162
  • [25] Cytochrome P450 3A polymorphisms and immunosuppressive drugs
    Thervet, E
    Legendre, C
    Beaune, P
    Anglicheau, D
    PHARMACOGENOMICS, 2005, 6 (01) : 37 - 47
  • [26] Role of cytochrome P450 enzymes in the metabolism of antineoplastic drugs
    Quinones S, Luis
    Rosero P, Mario
    Roco A, Angela
    Moreno T, Ivan
    Sasso A, Jaime
    Varela F, Nelson
    Caceres L, Dante
    Saavedra S, Ivan
    REVISTA MEDICA DE CHILE, 2008, 136 (10) : 1327 - 1335
  • [27] Prediction of Cytochrome P450 Mediated Metabolism of Designer Drugs
    Nielsen, Line Marie
    Linnet, Kristian
    Olsen, Lars
    Rydberg, Patrik
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2014, 14 (11) : 1365 - 1373
  • [28] A history of the roles of cytochrome P450 enzymes in the toxicity of drugs
    Guengerich, F. Peter
    TOXICOLOGICAL RESEARCH, 2021, 37 (01) : 1 - 23
  • [29] Designing better drugs: predicting cytochrome P450 metabolism
    de Groot, Marcel J.
    DRUG DISCOVERY TODAY, 2006, 11 (13-14) : 601 - 606
  • [30] USE OF DRUGS THAT ACT ON THE CYTOCHROME P450 SYSTEM IN THE ELDERLY
    Cabrera, Marcos A. S.
    Dip, Renata M.
    Furlan, Maira O.
    Rodrigues, Sara L.
    CLINICS, 2009, 64 (04) : 273 - 278